Focusing in on the past five trading days, shares have changed 2.44%. Oppenheimer Holdings, Inc. began coverage on Seattle Genetics in a report on Tuesday. If a company looks good after the research is complete, patience may still be desirable. For this reason, many traders with a high risk tolerance look to multiple measures of volatility to help inform their trade strategies. Investors will likely be tracking any consensus estimate changes heading into the next earnings period. "The company has a mixed record of earnings surprises in recent quarters". (NASDAQ:SGEN) for 1,225 shares. On Tuesday, August 25 the stock rating was maintained by William Blair with "Buy". Seattle Genetics Inc now has $8.79 billion valuation. Canada Pension Plan Invest Board holds 0.01% of its portfolio in Seattle Genetics, Inc. Initiates Coverage on Seattle Genetics, Inc. The rating was upgraded by Piper Jaffray to "Neutral" on Friday, October 30. (NYSE:VZ), 6 have Buy rating, 0 Sell and 19 Hold. Seattle Genetics now has a consensus rating of "Hold" and an average price target of $61.00. (NASDAQ:SGEN) rating on Monday, July 24.
Share prices are capable of moving sharply higher or lower in a very short amount of time. Zooming out to the 50-Day Simple Moving Average, we can see a difference of 51.67% from current stock levels. The company's market cap is $8.79 billion. Jefferies Group LLC reaffirmed a "buy" rating and set a $53.00 price objective on shares of Seattle Genetics in a research note on Thursday, July 27th. The business had revenue of $108.20 million for the quarter, compared to analyst estimates of $105.92 million. Seattle Genetics had a negative net margin of 47.38% and a negative return on equity of 32.87%. SGEN reported a change of 5.55% over the last week and performed 15.65% over the last month while its year to date (YTD) performance revealed an activity trend of 16.49%. On average, analysts forecast that Seattle Genetics will post ($1.69) earnings per share for the current year.Читайте также: Target Expands Google Express Offer Nationwide to Counter Amazon
Several analysts have released their opinion on Seattle Genetics, Inc. Recently, investment analysts covering the stock have updated the mean rating to 2.5. If you are accessing this story on another website, it was stolen and republished in violation of United States & worldwide copyright & trademark legislation. The firm earned "Sell" rating on Wednesday, November 18 by Goldman Sachs. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Vaughn B. Himes, CTO sold $530,900 worth of shares at an average price of $53.09 on Friday the 8th. The shares were sold at an average price of $53.22, for a total transaction of $532,200.00. The disclosure for this sale can be found here. Natixis Asset Mgmt owns 15,419 shares.
Seattle Genetics (NASDAQ:SGEN) opened at 61.47 on Tuesday. They expect $-0.42 earnings per share, down 82.61% or $0.19 from last year's $-0.23 per share. Finally, Janus Capital Management LLC lifted its position in shares of Seattle Genetics by 321.2% in the first quarter. Ameriprise Financial Inc. now owns 59,125 shares of the biotechnology company's stock worth $3,717,000 after purchasing an additional 36,157 shares during the period. Finally, M&T Bank Corp raised its holdings in Seattle Genetics by 7.3% in the first quarter. The stock grabbed 44 new institutional investments totaling 2,334,942 shares while 34 institutional investors sold out their entire positions totaling 1,374,022 shares. UBS Asset Management Americas Inc. raised its holdings in Seattle Genetics by 14.7% in the first quarter. The company's institutional ownership is monitored at 54.8 percent. Bnp Paribas Arbitrage Sa invested in 17,809 shares or 0% of the stock. (NASDAQ:SGEN) were released by: Nasdaq.com and their article: "Seattle Genetics' Adcetris Gets Breakthrough Therapy Status" published on October 03, 2017 as well as Nasdaq.com's news article titled: "Seattle Genetics' ADCETRIS Gets FDA Breakthrough Therapy Designation" with publication date: October 02, 2017. The Firm is engaged in the development and sale of pharmaceutical products on its own behalf or in collaboration with others. The Company's marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate.При любом использовании материалов сайта и дочерних проектов, гиперссылка на обязательна.
«» 2007 - 2017 Copyright.
Автоматизированное извлечение информации сайта запрещено.
Код для вставки в блог
- Walt Disney Company (The) (DIS) Upgraded to "Strong-Buy" at Vetr Inc
- Oxford to ban polluting cars in 'world's first' zero emissions zone
- Trump touts stock market gains, suggests he is 'reducing debt'
- Earnings Approximations to Watch: Regeneron Pharmaceuticals, Inc. (REGN), Abbott Laboratories (ABT)
- Cryptocurrency Bitcoin rockets above $7000 to all-time high
- Smith on top in Malaysia
- Microsoft has the BEST news for fans
- Revenue Approximations Analysis: Twenty-First Century Fox, Inc. (FOX), Dollar General Corporation (DG)
- Costs help Citi beat Wall Street view; consumer debts rise
- Things to Watch in Wells Fargo's Results